Ian Jones

SPCs: What it means to be protected by a patent

Further guidance has come from the CJEU on the disclosure requirements in a patent of a medicinal drug for it to be awarded a Supplementary Protection Certificate (SPC), and the associated market exclusivity, in Europe. Unlike the case for infringement, it is not enough for the medicinal drug, or “product”,...

Read more

UK SPCs: Beyond 2020

Supplementary Protection Certificates  (“SPCs”) can be obtained in the UK in the usual way throughout the rest of the Brexit transition period. But when we leave 2020, the process and the documents that may be relied upon are likely to change.This may depend upon ongoing EU-UK negotiations and any agreements...

Read more

Bittersweet News for Employee Compensation in the Pharmaceutical Sector

The UK Supreme Court’s decision in Shanks v Unilever has provided some guidance on the circumstances that may lead to an inventor being entitled to a financial reward from their employer under UK law. The court awarded Professor Shanks a £2 million pay-out after finding that a biosensor for measuring glucose...

Read more

SPCs: Waive goodbye to your protection

In Europe, Supplementary Protection Certificates (SPCs) compensate patentees for the inevitable delay in obtaining Marketing Authorisation by extending exclusivity for a marketable pharmaceutical or plant protection product by up to five years (five-and-a-half years for paediatric medicines) following the expiry of the related patent protection. Earlier this year, the EU...

Read more

Ligand Licenses VER250840 to Cumulus Oncology

Ligand Pharmaceuticals has announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialise VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Vernalis Design Platform (VDP). Under the terms of the agreement, Ligand will receive an upfront license fee, and...

Read more